Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received Class III medical device registration approval from the National Medical Products Administration on December 10, 2025 [1][3] - The collagen market in China has reached a scale of 200 billion, with projections to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high concentration of medical collagen at 45 mg/ml, ensuring strong support [5] - The product is made from high-purity bovine tendon collagen, which guarantees the integrity of the raw material [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper support for the skin [5] - The development team overcame several technical challenges, establishing 45 mg/ml as the optimal concentration to balance collagen network formation and safety [5] - The product maintains biological activity and structural integrity through meticulous production processes [5] Market Trends - The introduction of "Jiaoyuan Angel" is expected to shift the focus of collagen applications from immediate filling effects to a trend of nutritional tightening in the industry [7] - Yuansong Group has established a strong presence in the medical aesthetics sector with several successful products, positioning itself as a market leader [7] - Analysts predict that "Jiaoyuan Angel" could capture significant market share quickly, potentially becoming a dark horse in the medical aesthetics market by 2026 [7]

Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received regulatory approval on December 10 [1][3] - The collagen market has reached a scale of 200 billion and is projected to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high medical collagen concentration of 45 mg/ml, ensuring strong support [5] - The product uses collagen extracted from bovine tendons, ensuring high purity and structural integrity [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper network support for the skin [5] - The company has addressed industry challenges, establishing 45 mg/ml as the optimal concentration to balance efficacy and safety [5] Market Positioning - The collaboration signifies an upgrade in the synergy between clinical institutions and research enterprises, aiming to redefine the application of collagen in the market [6] - The focus is shifting from "volume enhancement" to "nutritional tightening," which is expected to become the mainstream trend in the collagen market [8] - Yuansong Group has previously launched several successful products in the medical beauty sector, positioning itself as a market leader [8] - "Jiaoyuan Angel" is anticipated to capture significant market share and potentially become a dark horse in the medical beauty market by 2026 due to its technological advantages and promotional capabilities [8]